ADMA Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ADMA Biologics
ADMA Stock  USD 17.95  0.12  0.66%   
ADMA Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ADMA Biologics' valuation are provided below:
Gross Profit
267.3 M
Profit Margin
0.4287
Market Capitalization
4.3 B
Enterprise Value Revenue
8.8472
Revenue
488.6 M
We have found one hundred twenty available fundamental signals for ADMA Biologics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of ADMA Biologics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself in the future. The current year's Market Cap is expected to grow to about 3.8 B. The current year's Enterprise Value is expected to grow to about 3.8 B

ADMA Biologics Total Revenue

514.94 Million

Check ADMA Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADMA Biologics' main balance sheet or income statement drivers, such as Interest Expense of 16.8 M, Other Operating Expenses of 347.1 M or Operating Income of 167.8 M, as well as many indicators such as Price To Sales Ratio of 11.31, Dividend Yield of 0.0694 or PTB Ratio of 10.82. ADMA financial statements analysis is a perfect complement when working with ADMA Biologics Valuation or Volatility modules.
  
Build AI portfolio with ADMA Stock
Check out the analysis of ADMA Biologics Correlation against competitors.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.

ADMA Biologics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets590.1 M562 M191.9 M
Slightly volatile
Short and Long Term Debt Total50.7 M94.4 M57.4 M
Slightly volatile
Total Current Liabilities67.1 M63.9 M23.2 M
Slightly volatile
Cash124.6 M118.6 M45.6 M
Slightly volatile
Common Stock Shares Outstanding360.7 M219 M170.1 M
Very volatile
Liabilities And Stockholders Equity590.1 M562 M192.2 M
Slightly volatile
Total Liabilities168.6 M160.6 M85.6 M
Slightly volatile
Total Current Assets400.2 M381.1 M136.6 M
Slightly volatile
Other Current Liabilities36.8 M35.1 M12.7 M
Slightly volatile
Cash And Short Term Investments124.6 M118.6 M46.7 M
Slightly volatile
Common Stock Total Equity19 K20 K23.9 K
Slightly volatile
Non Current Liabilities Total54.7 M96.7 M60 M
Slightly volatile
Other Stockholder Equity794 M756.2 M327.7 M
Slightly volatile
Common Stock29.1 K21.6 K24.7 K
Pretty Stable
Property Plant And Equipment Net76.5 M72.8 M32.5 M
Slightly volatile
Accounts Payable24.4 M23.3 M9 M
Slightly volatile
Non Current Assets Total189.9 M180.9 M55.5 M
Slightly volatile
Inventory205.6 M195.8 M71.5 M
Slightly volatile
Other Current Assets9.7 M9.2 M3.2 M
Slightly volatile
Property Plant And Equipment Gross117 M111.4 M39.6 M
Slightly volatile
Other Liabilities4 M4.2 M132.2 M
Pretty Stable
Long Term Debt60 M83.2 M50.6 M
Slightly volatile
Long Term Debt Total84 M80 M41 M
Slightly volatile
Capital Surpluse760.7 M724.5 M326.8 M
Slightly volatile
Capital Lease Obligations11.8 M11.2 M4.1 M
Slightly volatile
Deferred Long Term Liabilities2.3 M2.6 M2 M
Slightly volatile
Non Current Liabilities Other1.8 M1.9 M5 M
Very volatile
Short Term Debt1.2 M1.4 M972.4 K
Pretty Stable
Property Plant Equipment63.7 M67 M2.7 B
Pretty Stable
Current Deferred Revenue148.8 K164.4 K127.3 K
Slightly volatile
Deferred Long Term Asset Charges231.7 K312.4 K243 K
Slightly volatile
Short and Long Term Debt48.6 M46.2 M24.9 M
Slightly volatile
Net Invested Capital508.8 M484.6 M190.1 M
Slightly volatile
Net Working Capital163.2 M317.2 M120.2 M
Slightly volatile
Capital Stock17.3 K27.6 K11.3 K
Slightly volatile

ADMA Biologics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses347.1 M330.6 M116.5 M
Slightly volatile
Total Operating Expenses97.3 M92.7 M42.9 M
Slightly volatile
Selling General Administrative89.5 M85.2 M33 M
Slightly volatile
Depreciation And Amortization9.7 M9.3 M3.6 M
Slightly volatile
Total Revenue514.9 M490.4 M121.6 M
Slightly volatile
Research Development1.6 M1.6 M4.6 M
Slightly volatile
Cost Of Revenue249.8 M237.9 M73.7 M
Slightly volatile
Interest Income2.5 M2.4 M1.2 M
Very volatile
Non Recurring676.3 K760.9 K830.5 K
Slightly volatile
Reconciled Depreciation5.8 M9.3 M4.5 M
Slightly volatile

ADMA Biologics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow62 M59.1 M33.5 M
Slightly volatile
End Period Cash Flow124.6 M118.6 M46.1 M
Slightly volatile
Depreciation9.7 M9.3 M3.7 M
Slightly volatile
Stock Based Compensation16.4 M15.7 M4.5 M
Slightly volatile
Change To Netincome18.5 M17.6 M6.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.3110.7813.898
Slightly volatile
Dividend Yield0.06940.07810.0852
Slightly volatile
Days Sales Outstanding41.0238.5143.7629
Slightly volatile
Average Payables6.5 M11.5 M7.2 M
Slightly volatile
Stock Based Compensation To Revenue0.03490.03670.18
Slightly volatile
Capex To Depreciation1.971.231.6327
Very volatile
EV To Sales10.6710.7212.5085
Slightly volatile
Inventory Turnover1.361.41.1706
Pretty Stable
Days Of Inventory On Hand294270396
Slightly volatile
Payables Turnover9.679.215.09
Slightly volatile
Sales General And Administrative To Revenue1.41.521.4938
Slightly volatile
Average Inventory158.8 M151.3 M67.3 M
Slightly volatile
Research And Ddevelopement To Revenue0.00460.00490.9687
Slightly volatile
Capex To Revenue0.0220.02310.1059
Pretty Stable
Cash Per Share0.480.511.5467
Slightly volatile
Days Payables Outstanding38.9741.02191
Slightly volatile
Intangibles To Total Assets0.00890.00940.0504
Slightly volatile
Current Ratio3.75.375.7123
Very volatile
Receivables Turnover11.249.8112.7229
Slightly volatile
Graham Number4.284.815.2512
Slightly volatile
Capex Per Share0.07780.04230.0638
Very volatile
Average Receivables20.8 M19.8 M8.9 M
Slightly volatile
Revenue Per Share1.731.650.7901
Slightly volatile
Interest Debt Per Share0.450.471.2712
Slightly volatile
Debt To Assets0.180.190.4259
Slightly volatile
Operating Cycle332309438
Pretty Stable
Days Of Payables Outstanding38.9741.02191
Slightly volatile
Long Term Debt To Capitalization0.190.20.5296
Slightly volatile
Total Debt To Capitalization0.210.220.5277
Slightly volatile
Quick Ratio2.742.613.7603
Slightly volatile
Net Income Per E B T0.941.421.1613
Slightly volatile
Cash Ratio1.961.673.053
Slightly volatile
Days Of Inventory Outstanding294270396
Slightly volatile
Days Of Sales Outstanding41.0238.5143.7629
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.071.0241
Pretty Stable
Fixed Asset Turnover6.366.062.8663
Slightly volatile
Debt Ratio0.180.190.4259
Slightly volatile
Price Sales Ratio11.3110.7813.898
Slightly volatile
Asset Turnover0.820.790.36
Slightly volatile

ADMA Biologics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.8 B3.6 B841.4 M
Slightly volatile
Enterprise Value3.8 B3.6 B854.4 M
Slightly volatile

ADMA Fundamental Market Drivers

Forward Price Earnings28.9855
Cash And Short Term Investments103.1 M

ADMA Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ADMA Biologics Financial Statements

ADMA Biologics stakeholders use historical fundamental indicators, such as ADMA Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although ADMA Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ADMA Biologics' assets and liabilities are reflected in the revenues and expenses on ADMA Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ADMA Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue164.4 K148.8 K
Total Revenue490.4 M514.9 M
Cost Of Revenue237.9 M249.8 M
Stock Based Compensation To Revenue 0.04  0.03 
Sales General And Administrative To Revenue 1.52  1.40 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.65  1.73 
Ebit Per Revenue 0.29  0.31 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:
How To Invest In ADMA
Details
Is ADMA Stock a good investment?
Details
What is ADMA Biologics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of ADMA Biologics Correlation against competitors.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.86
Revenue Per Share
2.053
Quarterly Revenue Growth
0.12
Return On Assets
0.2176
Return On Equity
0.6317
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY